Exploring patient and clinician perspectives for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment: A qualitative study

Patient Education and Counseling · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles